Indivior Pharmaceuticals, Inc. (INDV)
36.18
-0.69
(-1.87%)
USD |
NASDAQ |
Aug 24, 16:00
36.18
0.00 (0.00%)
After-Hours: 20:00
Indivior Pharmaceuticals Enterprise Value : 4.638B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 4.638B |
| August 20, 2026 | 4.745B |
| August 19, 2026 | 4.894B |
| August 18, 2026 | 4.940B |
| August 17, 2026 | 4.898B |
| August 14, 2026 | 4.890B |
| August 13, 2026 | 4.797B |
| August 12, 2026 | 4.857B |
| August 11, 2026 | 4.822B |
| August 10, 2026 | 4.826B |
| August 07, 2026 | 4.868B |
| August 06, 2026 | 4.850B |
| August 05, 2026 | 4.857B |
| August 04, 2026 | 4.594B |
| August 03, 2026 | 4.697B |
| July 31, 2026 | 5.008B |
| July 30, 2026 | 5.033B |
| July 29, 2026 | 5.019B |
| July 28, 2026 | 5.124B |
| July 27, 2026 | 5.011B |
| July 24, 2026 | 5.069B |
| July 23, 2026 | 5.067B |
| July 22, 2026 | 5.060B |
| July 21, 2026 | 5.060B |
| July 20, 2026 | 4.903B |
| Date | Value |
|---|---|
| July 17, 2026 | 5.071B |
| July 16, 2026 | 5.077B |
| July 15, 2026 | 5.117B |
| July 14, 2026 | 5.034B |
| July 13, 2026 | 5.032B |
| July 10, 2026 | 5.066B |
| July 09, 2026 | 5.160B |
| July 08, 2026 | 5.112B |
| July 07, 2026 | 5.105B |
| July 06, 2026 | 5.006B |
| July 02, 2026 | 4.983B |
| July 01, 2026 | 5.036B |
| June 30, 2026 | 5.129B |
| June 29, 2026 | 5.368B |
| June 26, 2026 | 5.437B |
| June 25, 2026 | 5.371B |
| June 24, 2026 | 5.393B |
| June 23, 2026 | 5.209B |
| June 22, 2026 | 5.009B |
| June 18, 2026 | 5.007B |
| June 17, 2026 | 4.961B |
| June 16, 2026 | 4.971B |
| June 15, 2026 | 5.019B |
| June 12, 2026 | 5.029B |
| June 11, 2026 | 4.986B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Supernus Pharmaceuticals, Inc. | 2.335B |
| Liquidia Corp. | 6.013B |
| Corcept Therapeutics, Inc. | 12.89B |
| Amneal Pharmaceuticals, Inc. | 8.459B |
| Prestige Consumer Healthcare, Inc. | 4.409B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 122.00M |
| Revenue (Quarterly) | 343.00M |
| Total Expenses (Quarterly) | 221.00M |
| EPS Diluted (Quarterly) | 0.9839 |
| Gross Profit Margin (Quarterly) | 85.42% |
| Profit Margin (Quarterly) | 35.57% |
| Earnings Yield | 7.78% |
| Operating Earnings Yield | 11.60% |
| Normalized Earnings Yield | 9.863 |